Highlights, including post period
Phase 1b part of BGBC016 (1L NSCLC STK11m) progressed as planned with no new safety signals identified.
Regulatory approvals received from European countries for Phase 2a part of BGBC016 (1L NSCLC STK11m) allowing initiation in H1 2024 in accordance with guidance.
Significant reduction of operating expenses -
Year-end cash position of
Multiple Phase 2 bemcentinib data presented at prestigious oncology meetings, including ESMO, SITC and ASH.
New preclinical data in models of severe respiratory infections continues to support the potential of bemcentinib beyond NSCLC.
'Our cost discipline coupled with our recently executed warrant offering provides the company with funding through the end of 2024 and potentially into the second half of 2025 if all outstanding warrants are exercised in April 2024.'
Presentation and Financial Report
The Q4 2023 Financial Report is attached to this stock exchange announcement and the Report and the Q4 2023 presentation are available at the Company's website.
Contact:
Email: ir@bergenbio.com
Email: rune.skeie@bergenbio.com
Email: jl@lillebyfrisch.no
About
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
(C) 2024 Electronic News Publishing, source